Introduction
Spiro lactams have attracted considerable interest as conformationally constrained peptidomimetics 1,2 including type II' -turn mimetics. 3 Initially, 4.4-spiro lactams containing a pyrrolidone ring were reported. 4 More recently, 4.5-spiro lactams have been described as nonpeptide ligands of the SH3 domain, 5 5 or '-turn/distorted type-II -turn' mimetics, 6 inhibitors of myeloid differentiation factor 88, 7 and thyrotropin-releasing hormone. 8 The size and substitution of the lactam ring has been used to restrict the torsion  i+1 and  i+1 angles in the development of conformationally constrained mimetics containing a lactam. 4, 5, 9 Synthetic approaches to 4.5-spiro lactams have included thermal intramolecular ester aminolysis of proline derivatives, 10 cycloaddition reactions of aliphatic aldimines with methyl acrylate or N-methylmaleimide, 11 and hydrolysis of diazabicyclodecenes. 12 Synthetic approaches towards more complex polycyclic ring systems incorporating a 4.5-spiro lactam have included amide bond formation within an alkaloid natural product, 13 internal cyclisation via a carbanion to generate the natural product brevianamide 14 and generation of 4.5.4-spiro bicyclic ring systems. 15 4.5-Spiro lactams can be considered as mimetics of Pro-Ser. In this context 4.5-spiro lactams were targeted as potential inhibitors of Glycogen Phosphorylase a, which could derive from unique sequences (such as Pro-Ser) of the glycogen targeting subunit of PP1 known as G L . 16 Glycogen Phosphorylase is a molecular therapeutic target for treating hyperglycemia, 17 as it plays a critical in the formation of glucose-1-phosphate. Thus generation of a 4.5-spiro lactam scaffold with a C8 side chain substituent that would allow further generation of derivatives from both the N1 (proline) and C8 (ester) termini (Figure 1) , and potential formation of extended mimetics, was considered.
-turn
Previous methods for generating 4.5-spiro lactams have focused on generation of substituents on the lactam nitrogen. Reports of other Pro-Ser mimetics have been limited to sugar derived oliogmeric peptides 18 and (Z)-alkene dipeptides. 19 Herein we report a novel synthesis of a (±)-4.5-spiro lactam incorporating a C8 substituent introduced via the Bucher-Bergs reaction, and the screening of representative compounds against Glycogen Phosphorylase a. 
Discussion
Our initial approach considered the C2 alkylation of N-Boc-ProOBn 10 with N-Cbz-bromomethyl butyrate 4, to install an amino side chain at C2 of proline for subsequent synthetic transformation. Ring opening of amino butyrolactone 1 with hydrobromic acid, gave butyric acid 2 in excellent yield (88%). Esterification of 2 with thionyl chloride in methanol gave amino bromomethyl butyrate 3, which was N-Cbz protected to give methyl butyrate 4 20 in 69% overall yield from 1 (Scheme 1). Treatment of N-Cbz-bromomethyl butyrate 4 with sodium iodide in acetone 21 gave complete conversion to the Finkelstein product 5 (crude yield 99%), (Scheme 1) which was used directly in the attempted coupling with 10. With bromide 4, iodide 5 and proline 10 in hand, we attempted to form the spirocyclic center using the enolate anion of Boc-ProOBn 10. Treatment with LDA at 78 o C in THF, followed by addition of N-Cbz-bromomethyl butyrate 4 gave recovered starting materials. Disappointingly the use of alternate amide bases (LiHMDS), higher temperatures (0 °C) and the more reactive iodide analog of N-Cbz-bromomethyl butyrate 5 failed to give the desired product. In our hands poor recovery of starting materials was observed and was attributed to decomposition of iodide 5.
Lack of reaction between the anion of Boc-Pro-OBn 10 and alkylation agents 4 and 5, may be due to quenching of the anion by the carbamate NH proton. To circumvent this, N-dibenzyl bromomethyl butyrate 6 was generated from amino bromomethyl butyrate 3 (in 52% yield) through double reductive amination using benzaldehyde and NaBH(OAc) 3 (Scheme 1). Treatment of the anion of Boc-Pro-OBn 10 (using LiHDMS) with N-dibenzyl bromomethyl butyrate 6, gave recovered 6 and 10. An alternative acidic proton source may be the -proton of 4, 5, or 6. N-Cbz-Bromomethyl butyrate 4 was treated with one equivalent of LiHDMS then benzyl bromide to trap and identify the monoanion of 4. However, cyclopropane 7 24 was isolated (76%). X-ray analysis of the formed crystals of 7 confirmed the structure of cyclopropane 7 25 (Scheme 1). Formation of 7 occurs through nucleophilic substitution of the bromine atom of 4 by the -anion. The simple alkylating agents, halides 4, 5, and 6, were not suitable for reaction with N-Boc-Pro-OBn and a more activated alkylating agent, such as allyl bromide, was explored next.
Generation of the anion of 10 using LDA at 78 o C, followed by addition of allyl bromide gave 2-allyl-Boc-Pro-OBn 15.
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Attempted borane-methyl sulfide reduction and direct PCC oxidation of 15 to Boc-Pro-OBn propanal 17 15 (Scheme 3) gave very poor yields (<5% of 17, by mass-spectrometry, as part of a complex mixture). Likewise, hydroboration of 15 with borane.THF followed by basic hydrogen peroxide workup at 0 o C to obtain alcohol 16 resulted in the formation of a complex mixture (Scheme 3). The unexpected decomposition of 2-allylBoc-Pro-OBn 15 led us to consider the methyl ester group as the carboxyl protecting group for N-Boc-proline 9, the use of which had been previously reported. 26 Treatment of Pro-OMe 11 with di-tert-butyl dicarbonate gave NBoc-Pro-OMe 12 26, 27 (Scheme 2). Generation of the anion of 12 using LiHDMS at 78 o C, followed by addition of allyl bromide for 2 h gave 2-allyl-Boc-Pro-OMe 18.
26 (Scheme 3). Hydroboration of 18 with borane.THF followed by basic hydrogen peroxide workup at 0 o C gave a complex mixture. In contrast, formation of (2-methylbutyl) 2 borane in situ from 2-methylbutene and borane-THF 28 and reaction with 18, followed by basic hydrogen peroxide workup at 0 o C gave alcohol 19 29 (79%). Alcohol 19 was cleanly converted into aldehyde 20 28 (80%) by Swern oxidation (Scheme 3).
With the key synthon aldehyde 20 in hand, the generation of a C-8 substituted 4.5-spiro lactam was explored. Treatment of aldehyde 20 with potassium cyanide and ammonium carbonate in a Bucherer-Bergs reaction gave hydantoin 24 (Scheme 4). In some cases an intermediate amino nitrile (based on 13 C NMR spectroscopic evidence; signal at 120 ppm) was observed in the product mixture. This was attributed to insufficient carbon dioxide concentration in situ. In these cases, further treatment of a methanolic solution of the cyanohydrin intermediate with carbon dioxide gas led to complete conversion to hydantoin 24. Hydantoin 24 was reacted with di-tert-butyl dicarbonate in the presence of DMAP, and completion of the reaction was monitored by mass spectrometry. The di-Boc 25 is necessary for the hydrolysis step to be successful as the Boc groups promote hydantoin ring opening. Subsequent direct hydrolysis of 25 was carried out with potassium hydroxide using a mild two-step procedure. 30 Unfortunately, a complex mixture of products was obtained in which amino acid 31 (typically <5%) was detectable only by mass spectrometry. Amino acid 31 was unable to be isolated from this mixture, thus use of an alternate protecting group, CBz, was considered.
Proline was treated with benzylchloroformate in base to generate Cbz-Pro-OH 13, 31 treatment of 13 with catalytic sulfuric acid in methanol generated Cbz-Pro-OMe 14 32 (Scheme 2). Generation of the anion of 14, followed by addition of allyl bromide gave 2-allyl-Cbz-Pro-OMe 21.
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(Scheme 3). Reaction of (2-methylbutyl) 2 borane generated in situ with 21, followed by basic hydrogen peroxide workup at 0 o C gave alcohol 22 29 in excellent yield (80%). Alcohol 22 was cleanly converted into the previously unknown aldehyde 23 (66%) by Swern oxidation (Scheme 3). Treatment of aldehyde 23 under the Bucherer-Bergs reaction conditions gave hydantoin 26. Reaction of 26 with ditert-butyl dicarbonate and DMAP gave N,N-di-Boc hydantoin 27 (Scheme 4). Hydrolysis of 27 with potassium hydroxide followed by an acidic workup gave amino acid 30 in a modest but synthetically usable yield (40%).
It was envisaged that lactamisation should occur via heating only. However heating 30 in toluene returned unreacted starting material 30. It was noted that 30 was moderately insoluble in toluene (even at reflux temperatures) therefore heating 30 in methanol in a pressure vessel at 100, 120 or 140 o C was used to promote cyclization. Disappointingly, only the reaction carried out at 140 o C gave traces of a mixture of 4.5-spiro lactams 28 and 29, as determined by mass spectral analysis. Instead, amino acid 30 was treated with methanol, molecular sieves (3 Å) and heated at 140 o C in a sealed reaction vessel. 4.5-Spiro lactams 28 and 29 were obtained in a combined yield of 50% from N,N-di-Boc hydantoin 27 (Scheme 4). Analytical samples of 4.5-spiro lactams 28 and 29 were obtained using silica chromatography in isolated yields of 2% and 13%, respectively. For synthetic purposes, spiro lactams 28 and 29 were used after purification by alumina chromatography, and as a diastereomeric mixture.
4.5-Spiro lactams 28 and 29 were formed in a ratio of 16:83 respectively, as determined by integration of key peaks in the 1 H NMR spectrum. The structures of 28 and 29 were determined by COSY, HSQC, and HMBC and NOESY NMR spectroscopy. Formation of the spiro lactam ring was confirmed by a key correlation between C-6 (172.9 ppm for 29;  176.1 ppm for 28) and H-8 (4.2 ppm for 29;  4.18 ppm for 28) in the HMBC spectrum. In the 1 H NMR spectrum of spiro lactam 28, H8 displayed axial-equatorial and equatorial-equatorial coupling constants of 5.5 and <1 Hz respectively, which indicated that H8 was in a pseudo equatorial orientation for 28. In the spectum of 28 although one set of signals for an equatorial H8 was observed, two sets of signals for H10ax/H10eq and OMe were observed. By comparison in the 1 H NMR spectrum of spiro lactam 29, H8 displayed an axial-axial and axial-equatorial coupling constants of 11.7 and 4.7 Hz respectively which indicated that H8 was in a pseudo axial orientation for 29. Again, only one set of signals for an axial H8 but two sets of signals for H10ax/H10eq and OMe were observed. The duplication of signals suggested that both 28 and 29 were epimeric mixtures.
The NOESY spectra of 28 revealed correlations between H4 and H9 (2.09 -2.18 ppm and 2.18 -2.25 ppm); H2 and H3 (3.54 -3.60 ppm and 1.84 -2.06 ppm) and H8 and H9/H9 (4.14 ppm and 2.18 -2.25/2.26 -2.38 ppm), which suggested that the relative orientation of the pyrroline N and the ester groups were cis in 28 ( Figure 2a ). The NOESY spectra of 29 revealed correlations between H2 and H10 (3.54 -5.61 ppm and 1.89 -2.02 ppm) and H8 and H10 (4.24 ppm and 2.14 -2.32 ppm) (Figure 2b ), but the relative stereochemistry of 29 could not be unambiguously determined. However, if the relative orientation of the N-Cbz and ester groups are cis in 28, it follows that they must be trans in 29. This is consistent with the relative amounts of 28 and 29 formed. It would be expected that the trans isomer would be the more stable and therefore the major isomer formed.
In order to demonstrate the potential for generation of derivatives via peptide chemistry, both C and N termini must be orthogonally protected. Treatment of spiro lactams 28 and 29 with palladium-on-carbon, in methanol under an atmosphere of hydrogen gas, gave a white intractable gum. Variation of the reaction conditions to include catalytic sulfuric acid resulted in the formation of spiro lactam ester 32 (85%) (Scheme 5). Spiro lactams 28 and 29 were treated with barium hydroxide and carbon dioxide, upon workup spiro lactam acid 33 was isolated in 60% yield (Scheme 5).
The formation of spiro methyl ester 32 and spiro acid 33 achieved selective deprotection of 4.5-spiro lactams 28 and 29, unmasking the carboxylic acid or amine groups. Extension of the spiro lactam scaffold through either the carboxylic acid group of 33 and amine group of 32 could lead to the generation of further spiro derivatives, and is currently being examined as part of further work.
Bioassay
Spiro lactams 28, 29, 32 and 33 were screened against RMGPa using an inhibition assay measured in the direction of glycogen synthesis. Caffeine was used as the internal standard in the assay. Benchmarking each assay against caffeine allowed some conclusions to be drawn. The GPa assay results (Table 1) showed that the mixture of spiro lactams 28/29 gave an IC 50 of 7.43 M (caffeine standard 288 M). 13 C NMR spectra showed that the key peaks of C2, C4, and C3 of the amino acid 30 were not present in the spiro lactams 28/29 spectrum. This confirmed that 30 and 28/29 were discrete compounds and that compound 29 is the active component bioactivity of the individual compound. The variance in activity for 28/29 as compared to the individual compounds 28 and 29 was interesting, and suggests that the stereochemical orientation of key functional groups on the spiro scaffold influenced the observed activity. From the Lipinski calculations it was noted that there were no correlations between inhibition levels and properties of TPSA, lipophilicity (Log P) and solubility (Log S) ( Table 1 ). This is illustrated by the comparison of compounds 28 and 29 (Table 1) .
Conclusion
Spiro lactams 28/29 were readily generated in a 9 step process from 8 in overall yield of 5.8%. Spiro lactams 28/29 could be selectively deprotected to allow for further derivatives or incorporation into a parent peptide. Spiro lactam 28 displayed moderate activity against RMGPa. This suggests future exploration of N-and C8-substituted spiro lactam 28 may be of interest in the development of potential inhibitors of GPa.
5.Experimental

General Procedure.
Starting materials were obtained commercially -amino--butyrolactone hydrobromide 1 were purchased from Aldrich. All solvents were dried by standard methods.
1 H NMR (400 MHz) and 13 C NMR (100 MHz) spectra were recorded in the deuterated solvents indicated. Chemical shifts are reported in parts per million (unitsrelative to the reported solvent as an internal standard (eg; CDCl 3 ( 13 C, 77.0 ppm). 1 H NMR and
13
C NMR spectra spectral assignments are supported by gCOSY, gHSQC, and gHMBC analysis. Mass spectral data, LRMS were obtained by electrospray ionization (ESI). For preparative scale chromatography silica gel (60-200 mesh) was used. Melting points are uncorrected. (6) Benzaldehyde (223 mg, 2.10 mmol, 2.5 equiv) was added to a solution of the free amine of 3 (166 mg, 0.850 mmol) in CH 2 Cl 2 (6 mL) and the solution stirred for 1 hr. Sodium triacetoxy borohydride (445 mg, 2.10 mmol, 2.5 equiv) was added and the suspension stirred at rt for 16 hr. Sodium carbonate (saturated aqueous solution, 10 mL) was added and the biphasic suspension stirred for 1 hr. The reaction was diluted with water (5 mL) then extracted with ethyl acetate (3 × 10 mL), brine (10 mL), dried (MgSO 4 , anhydrous). The solvent was removed in vacuo to give a colourless oil (346 mg). The crude oil was retreated with sodium triacetoxy borohydride (445 mg, 2.10 mmol) in CH 2 Cl 2 (6 mL) and stirred at room temperature for 16 hr. The solution was worked up as above and the crude product obtained as a colourless oil (322 mg (15) . Boc-Pro-OBn 10 (100 mg, 0.327 mmol, 1.0 equiv) was added dropwise to a solution of LDA (360 L, 0.721 mmol, 2.2 equiv) in dry THF (4 mL) under an atmosphere of nitrogen at -78 °C. The reaction was stirred for 1 hr, warmed to 0 °C, and stirred for 5 mins. Allyl bromide (33 L, 0.393 mmol, 1.2 equiv) was added and the reaction stirred at rt for 12 hr. The reaction was diluted with water (5 mL) and extracted with ethyl acetate (3 × 10 mL). The combined organic layers were washed with brine (10 mL), dried (MgSO 4 , anhydrous) and the solvent removed in vacuo to give clear oil. Purification of the oil by silica gel column chromatography (hexane/ethyl acetate/Et 3 N, 89:10:1) gave 15 ( 
Experimental for known compounds. See supporting information.
Experimental for compounds.
(S)-Methyl 4-bromo-2-(dibenzylamino)butanoate
), 33.0 (C3), 30.2 (C4); LRMS (ESI) m/z 376 (100, MH + ), 378 (97%, MH + ).
1-tert-Butyl 2-benzyl 2-allylpyrrolidine-1,2-dicarboxylate
1-tert-Butyl 2-methyl 2-(2'-(2",5"-dioxoimidazolidin-4"-yl)ethyl)pyrrolidine-1,2-dicarboxylate (24).
Compound 20 (0.587 g, 2.06 mmol, 1 equiv) was dissolved in methanol (5 mL), and water (3 mL), then placed under a nitrogen flow. (NH 4 ) 2 CO 3 (99 mg, 1.03 mmol, 5 equiv) was added and the reaction stirred until the carbonate dissolved. KCN (aqueous solution, 2.21 M, 1.12 mL, 1.2 equiv) was added dropwise over 10 mins. The reaction was sealed with a glass stopper and stirred at rt for 48 hr. The solvent was concentrated in vacuo to give an oil. The oil was washed with water (10 mL), and the water layer was extracted with DCM (3 × 30 mL). The combined organic layers were washed with brine (50 mL), dried (MgSO 4 , anhydrous) and the solvent was removed in vacuo. (25) . DMAP (2.5 mg, 0.022 mmol, 0.05 equiv) was added to a solution of 24 (150 mg, 0.423 mmol, 1.0 equiv) in THF (anhydrous, 5 mL) under a nitrogen atmosphere. The reaction was stirred, cooled to 0 °C and di-tert-butyl dicarbonate (0.461 g, 2.15 mmol, 5.0 equiv) was added. After 16 hr the solvent was removed in vacuo. (23) . A solution of DMSO (4.60 mL, 64.5 mmol, 3 equiv) in DCM (25 mL, anhydrous) was added to a solution of oxalyl chloride (2.80 mL, 32.3 mmol, 1.5 equiv) in DCM (anhydrous, 25 mL) at 78 ⁰C over a period of 10 mins. The reaction was stirred at 78 °C for 10 mins. Compound 22 (6.90 mL, 21.5 mmol, 1 equiv) in DCM (100 mL, anhydrous) was added slowly at 78 ⁰C and the reaction stirred for 1 hr at 78 °C. Et 3 N (14.96 mL, 107.5 mmol, 5 equiv) was added. The reaction was warmed to rt then stirred for 30 hr. The reaction was diluted with water (50 mL), and the aqueous layer separated. 
Di-tert-butyl 4-(2'-(1"-(tert-butoxycarbonyl)-2"-(methoxycarbonyl)pyrrolidin-2"-yl)ethyl)-2',5'-dioxoimidazolidine-1',3'-dicarboxylate
1-Benzyl 2-methyl 2-(2-formylethyl)pyrrolidine-1,2-dicarboxylate
1-Benzyl 2-methyl 2-(2'-(2"
,5"-dioxoimidazolidin-4"-yl)ethyl)pyrrolidine-1,2-dicarboxylate (26) (NH 4 ) 2 CO 3 (14.3 g, 90.8 mmol, 11 equiv) was added to compound 23 (2.63 g, 8.25 mmol, 1 equiv) in methanol (20 mL) and water (17.5 mL) under a flow of nitrogen gas. The reaction was stirred until a homogenous solution was obtained. Aqueous KCN (2.21 M, 4.50 mL, 1.2 equiv) was added dropwise over 10 mins. The reaction was sealed with a glass stopper and stirred at rt for 84 hr. The solvent was concentrated in vacuo to give an oil which was washed with water (20 mL). The organic layer was extracted with DCM (3 × 60 mL). The combined organic layers were washed with brine (50 mL), dried (MgSO 4 , anhydrous) and the solvent was removed in vacuo. Purification of the crude oil by silica gel column chromatography (hexane/ethyl acetate, 27:73) gave 26 (3.2 g, 86%) as a colourless tacky gum; R f (hexane/ethyl acetate, 27:73) 0.36;  max (nujol) dec.; Conformer 1 (30%) δ H (400 MHz, CDCl 3 ) 1.60-1.70 (1H, m, H4), 1.70-1.90 (3H, m, H4, H2'), 1.90-2. 10 (3H, m, H3, H1'), 2.22-2.35 (1H, m, H3), 3.40 (2H, m, H5),  3.60 (3H, s, OCH 3 ), 3.89-4.05 (1H, m, H4" 70 (1H, m, H4), 1.70-1.90 (3H, m, H4, H2'), 1.90-2.10  (3H, m, H3, H1'), 2.22-2.35 (1H, m, H3), 3.40-3.45 (2H, m, H5 (27) . Di-tert-butyl dicarbonate (1.40 g, 6.40 mmol, 5 eq) was added to a solution of 26 (0.500 g, 1.29 mmol, 1.0 eq) in THF (anhydrous, 10 mL) at rt. A portion of DMAP (2.80 mg, 0.0230 mmol, 0.018 eq), followed by Et 3 N (0.195 mL, 1.40 mmol, 1.1 eq) were added. After stirring at rt for 3 hr, a second portion of DMAP (2.80 mg, 0.0230 mmol, 0.018 eq) was added and the resulting solution was stirred at rt for 16 hr. The reaction solvent was removed in vacuo. The residual oil was dissolved in chloroform (50 mL). The organic layer was washed with aqueous HCl (1 M, 20 mL), aqueous NaHCO 3 (50 mL, saturated), brine (50 mL), water (3 × 30 mL), and dried (MgSO 4 , anhydrous) then concentrated in vacuo. (30) . Aqueous KOH solution (2.00 M, 13.0 mL) was added to a colourless solution of compound 27 (750 mg, 1.27 mmol) in THF (10 mL) at rt. The reaction was stirred for 20 hr, then diluted with water (15 mL) and ethyl acetate (15 mL (33) . Compounds 28/29 (46 mg, 0.125 mmol, 1 equiv) in THF (0.5 mL) were added to Ba(OH) 2 .H 2 O (123 mg, 0.718 mmol, 5.7 equiv) in water (3 mL). The reaction mixture was stirred at rt for 1 hr, then carbon dioxide was bubbled through the reaction mixture for 1 hr. A precipitate formed which was removed by filtration and washed with water. The water layer was lypholised to dryness. The residue was dissolved in methanol (10 mL), filtered and concentrated in vacuo. Compound 33 was obtained as a white gum (27 mg, 60%). Diastereomer mix (a and b) in a 6:4 ratio respectively;  max (nujol) dec.; δ H (300 MHz, CD 3 GPa assay. Rabbit Muscle Glycogen Phosphorylase a (from Sigma, 0.475ug/mL) activity was measured in the direction of glycogen synthesis by the release of phosphate from glucose-1-phosphate 34 using a 384 well plate at 22 °C in 45 µL of buffer containing 50 mM Hepes (pH 7.2), 100 mM KCl, 2.5 mM ethylene glycol tetraacetic acid (EGTA), 2.5 mM MgCl 2 , 0.25 mM glucose-1-phosphate, and 1 mg/mL glycogen with a 30 min incubation time. Phosphate was measured at 620 nm, 5 min after the addition of 150 µL of 1 M aqueous HCl containing 10 mg/mL ammonium molybdate and 0.38 mg/mL malachite green. 35 Test compounds (obtained after HPLC and with TFA removed) were added to the assay in 5µL of 14% DMSO. Compounds were tested against a caffeine standard in 11pt concentration-response curve in duplicate on two separate occasions, with a Hill slope between 0.5 and 3.0 and Z' values of ~0.8. Compounds were screened with maximal concentrations of 0.22 mM (1-14), and 22 mM (5, 6, 15-24) and were carefully monitored for signs of insolubility of a compound under assay conditions. Where an estimated IC 50 could not be determined, the % inhibition observed at maximal concentration was reported.
Di-tert-butyl 4-(2'-(1"-((benzyloxy)carbonyl)-2"-(methoxycarbonyl)pyrrolidin-2'-yl)ethyl)-2,5-dioxoimidazolidine-1,3-dicarboxylate
4-(1'-((Benzyloxy)carbonyl)-2'-(methoxycarbonyl) pyrrolidin-2'-yl)-2-aminobutanoic acid
